

Special Issue

Epigenetic Regulation in Tumors

Message from the Guest Editor

Cancer is a multifactorial and a complex disease characterized at molecular level not only by genetic mutations but also by epigenetic alterations. As already known, epigenetics plays a pivotal role in tumor development, progression, and resistance to therapy. Dysregulated mechanisms such as DNA methylation, histone modifications, and non-coding RNAs contribute to oncogenic transformation. In the 'omics' era, studying the altered epigenome of cancer cells could reveal effective biomarkers for precision medicine and guide the development of new anticancer therapies. Artificial intelligence has the potential to accelerate the discovery of tumor epigenetic biomarkers and the development of personalized treatments. Key topics covered in this issue include, but are not limited to: epigenetic mechanisms driving tumorigenesis, novel epigenetic biomarkers for cancer diagnosis and prognosis, therapeutic targeting of the epigenome, epigenetic interactions with the tumor microenvironment, multi-omics and bioinformatics approaches in cancer epigenetics.

Guest Editor

Dr. Anca Botezatu

Molecular Virology Department, Stefan S. Nicolau Institute of Virology, Bucharest, Romania

Deadline for manuscript submissions

25 September 2026

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/232367

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))